Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antisense oligonucleotides: a new therapeutic approach]

P Guinot1, J Temsamani

  • 1Hybridon Europe, Paris, France.

Pathologie-Biologie
|October 14, 1998
PubMed
Summary

Antisense oligonucleotides offer targeted gene expression inhibition for various diseases. Advances in synthesis and clinical trials are improving their safety and effectiveness as therapeutic agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Target engagement and intracellular delivery of mono- and bivalent LDL receptor-binding peptide-cargo conjugates: Implications for the rational design of new targeted drug therapies.

Journal of controlled release : official journal of the Controlled Release Society·2019
Same author

Detection of hazardous weight-loss substances in adulterated slimming formulations using ultra-high-pressure liquid chromatography with diode-array detection.

Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment·2011
Same author

Comparative pharmacokinetics of antisense oligonucleotides.

Methods in molecular medicine·2011
Same author

Antisense approach for the treatment of cytomegalovirus infection.

Expert opinion on investigational drugs·2005
Same author

Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties.

Journal of neurochemistry·2005
Same author

Vector-mediated drug delivery to the brain.

Expert opinion on biological therapy·2001

Area of Science:

  • Molecular Biology
  • Pharmacology
  • Biotechnology

Background:

  • Antisense oligonucleotides (ASOs) are therapeutic agents that inhibit gene expression.
  • They function by binding to target nucleic acids with high specificity.
  • Significant advancements have been made in ASO synthesis and manufacturing.

Purpose of the Study:

  • To review the progress and potential of antisense oligonucleotide technology.
  • To highlight the therapeutic applications of ASOs in diverse medical fields.
  • To discuss the impact of ongoing clinical trials on future ASO development.

Main Methods:

  • Review of scientific literature on antisense oligonucleotide technology.
  • Analysis of data from preclinical and clinical studies.
  • Evaluation of advancements in oligonucleotide synthesis and chemistry.

Main Results:

  • ASOs have demonstrated efficacy in modulating gene expression for infectious diseases, cancer, and inflammation.
  • Over a dozen clinical trials involving ASOs have been initiated recently.
  • Clinical trial data are guiding the development of improved ASO chemistries.

Conclusions:

  • Antisense oligonucleotide technology has progressed significantly, showing therapeutic promise.
  • Ongoing clinical trials are crucial for refining ASO safety and efficacy.
  • Future developments in ASO chemistry are expected to enhance their therapeutic profile.

Related Experiment Videos